Find comprehensive information on Empagliflozin (Jardiance) for healthcare professionals. Learn about Empagliflozin usage, clinical documentation guidelines, medical coding for Empagliflozin, and Jardiance prescription information. This resource covers essential details for accurate Empagliflozin coding and documentation in medical records.
Also known as
Type 2 diabetes mellitus
Empagliflozin is used to treat type 2 diabetes.
Heart failure
Empagliflozin is used to reduce heart failure risk in certain patients.
Glomerular disorders
Empagliflozin can slow progression of chronic kidney disease.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is Empagliflozin being used to treat type 2 diabetes mellitus?
Yes
Any documented complications?
No
Is Empagliflozin used for heart failure?
When to use each related code
| Description |
|---|
| SGLT2 inhibitor for type 2 diabetes. |
| DPP-4 inhibitor for type 2 diabetes. |
| GLP-1 receptor agonist for type 2 diabetes. |
Coding risk for E/Empagliflozin/Jardiance if prescribed for non-FDA-approved indications, impacting reimbursement and compliance.
Incorrect coding for Empagliflozin dosage strength may lead to claim denials. CDI crucial for accurate documentation.
Chronic Kidney Disease (CKD) stage impacts Empagliflozin use. Accurate coding and CDI essential for compliant billing.
Q: What are the key clinical considerations for initiating Empagliflozin (Jardiance) therapy in patients with type 2 diabetes and chronic kidney disease?
A: Initiating Empagliflozin in patients with type 2 diabetes and chronic kidney disease requires careful consideration of several factors. First, assess the patient's estimated glomerular filtration rate (eGFR) and current kidney function stage. Empagliflozin is generally recommended for patients with an eGFR above 20 mL/min/1.73 m2, but dose adjustments may be necessary depending on the specific eGFR range. Second, monitor for potential adverse events such as volume depletion, hypotension, and genitourinary infections. Closely observe electrolyte levels, particularly potassium and magnesium. Third, evaluate for potential contraindications, such as end-stage renal disease or dialysis dependence. Lastly, consider patient-specific factors, including comorbidities, medication interactions, and patient preferences when making treatment decisions. Explore how Empagliflozin's cardiorenal benefits can be leveraged in this specific patient population to improve outcomes. Consider implementing a shared decision-making approach to discuss the risks and benefits with the patient.
Q: How does Empagliflozin (Jardiance) compare to other SGLT2 inhibitors in terms of efficacy and safety for managing heart failure with reduced ejection fraction (HFrEF) in patients with and without diabetes?
A: Empagliflozin has demonstrated robust efficacy in reducing cardiovascular death and hospitalization for heart failure in patients with HFrEF, both with and without type 2 diabetes. While direct head-to-head comparisons across all SGLT2 inhibitors are limited, Empagliflozin has shown comparable or superior outcomes in reducing cardiovascular events compared to other SGLT2 inhibitors in several large-scale clinical trials, including the EMPEROR-Reduced and DAPA-HF trials. The safety profile of Empagliflozin in HFrEF is generally similar to other SGLT2 inhibitors, with potential risks of genitourinary infections, volume depletion, and hypotension. However, the risk of diabetic ketoacidosis appears to be lower with Empagliflozin compared to some other SGLT2 inhibitors. Learn more about the specific trial data comparing Empagliflozin to other SGLT2 inhibitors in the management of HFrEF. Consider implementing a patient-centered approach when selecting the most appropriate SGLT2 inhibitor based on individual patient characteristics and clinical guidelines.
Patient presents for follow-up management of type 2 diabetes mellitus. The patient is currently prescribed Empagliflozin (Jardiance), a sodium-glucose cotransporter-2 (SGLT2) inhibitor, for glycemic control. Discussion today focused on medication adherence, efficacy, and potential side effects. The patient reports consistent medication compliance and denies any genitourinary infections, hypotension, or other adverse effects. Current HbA1c is 7.2%, demonstrating improvement in glycemic control since initiating Empagliflozin therapy. Vital signs stable. Assessment includes review of renal function, blood pressure, and volume status, all of which are within normal limits. Plan to continue Empagliflozin at the current dose. Patient education provided regarding importance of regular blood glucose monitoring, healthy diet, and exercise for diabetes management. Emphasis on signs and symptoms of hypoglycemia and hyperglycemia, as well as potential adverse events associated with SGLT2 inhibitors, such as euglycemic diabetic ketoacidosis, urinary tract infections, and dehydration. Follow-up scheduled in three months to reassess glycemic control and adjust treatment plan as needed. ICD-10 code E11.9 for type 2 diabetes mellitus without complications documented.